One pill to beat worms? new drug emodepside takes on mebendazole
NCT ID NCT06736691
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase 3 trial tests whether a single dose of emodepside can cure soil-transmitted worm infections (like whipworm, hookworm, and roundworm) better than the standard 3-day course of mebendazole. About 315 adolescents and adults with confirmed infections will receive either emodepside or mebendazole, and researchers will check stool samples to see if the worms are gone. The goal is to find a simpler, more effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICHURIS TRICHIURA; INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Public Health Laboratory - Ivo de Carneri (PHL-IdC)
Chake Chake, Tanzania
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emodepside
What this could lead to
If it works, this could offer a simpler, single-dose treatment for common worm infections, potentially improving cure rates and reducing the need for multiple doses.
What could go wrong
This is a single-center trial with 315 participants, so results may not apply broadly. Emodepside is new for this use, and side effects or lower-than-expected efficacy are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.